Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study

Open access
Rimola, Antoni, Salmerón, Joan M., Clemente, Gerardo, Rodrigo, Luis, Obrador, Antoni, Miranda, Luisa M., Guarner, Carlos, Planas, Ramon, Solá, Ricard, Vargas, Victor, Casafont, Fernando, Marco, Francesc, Navasa, Miquel, Bañares, Rafael, Arroyo, Vicente, Rodés, Joan·1995·Hepatology

Abstract

Cefotaxime (CTX) is considered one of the first-choice antibiotics in the therapy of spontaneous bacterial peritonitis (SBP) in cirrhosis. Because CTX is largely metabolized in the liver, this drug may also be effective in SBP by administering lower doses than those habitually used. To investigate this possibility, a prospective, randomized, multicenter study was performed to compare the therapeutic efficacy of two different dosages of CTX in 143 patients with SBP: 71 (group I) were allocated to receive a high dose (2 g every 6 hours, which is one of the most frequently recommended doses in this infection), and 72 (group II) were allocated to receive a low dose (2 g every 12 hours). At inclusion, both groups were similar in relation to clinical and laboratory data, with the exception of a higher incidence of positive ascitic fluid culture in group I than in group H (59% vs. 40%; P = .029). The rate of infection resolution was similar for both groups (77% vs. 79%). Hospital survival was also similar in both groups (69% vs. 79%). No difference was observed between patients with positive or negative ascitic fluid cultures with regard to infection resolution and patient survival. The duration of antibiotic therapy was similar in both groups (9.0 ± 3.3 days in group I vs. 8.8 ± 3.1 days in group II). In a subset of 13 patients from group I and 11 patients from group II CTX levels were determined in serum (peak and trough) and ascitic fluid (concomitantly with trough serum). Peak serum levels were similar in patients from both groups. In contrast, trough serum and/or ascitic fluid levels were significantly lower or more frequently undetectable in group II patients than in group I patients. Nevertheless, this feature did not correlate with infection resolution or patient survival. These results indicate that the High efficacy of CTX in SBP can be maintained by using doses lower than those habitually recommended.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.1840210312

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 181

Metadata

Authors
Rimola, A., Salmerón, J. M., Clemente, G., Rodrigo, L., Obrador, A., Miranda, L. M., Guarner, C., Planas, R., Solá, R., Vargas, V., Casafont, F., Marco, F., Navasa, M., Bañares, R., Arroyo, V., & Rodés, J.
Venue
Hepatology
Published
1995-03
Volume
21
Issue
3
Pages
674-679
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2106227553
Cited by
181
References
1
FWCI
3.18
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. https://app.cochat.ai/papers/10.1002/hep.1840210312
The paper
Rimola, A., Salmerón, J. M., Clemente, G., Rodrigo, L., Obrador, A., Miranda, L. M., Guarner, C., Planas, R., Solá, R., Vargas, V., Casafont, F., Marco, F., Navasa, M., Bañares, R., Arroyo, V., & Rodés, J. (1995). Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology. https://doi.org/10.1002/hep.1840210312

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.